Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Affiliations:

Tyra Biosciences, Inc.

Carlsbad, CA, USA

Articles by Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

ByErik Goluboff, MD, MBA, Tyra Biosciences, Inc.

March 30th 2026

Latest Updated Articles

Trending on Urology Times

SBRT, prostatectomy show comparable long-term disease control in PACE-A trial

Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR

A rising tide that lifts all boats: PSMA-PET and genomic testing for prostate cancer

Pivotal trial launches of GRPR-targeted PET imaging agent in prostate cancer

Armine K. Smith, MD, on addressing sexual health in modern bladder cancer care